Australian biotechnology company Vaxine has collaborated with South Korean biopharma firm Medytox for the development and commercialisation of its Covid-19 vaccine candidate, COVAX-19.
COVAX-19 uses Vaxine’s Advax adjuvant technology in combination with a recombinant SARS-CoV-2 spike protein. Currently, the vaccine candidate is undergoing late-stage animal studies in Australia, as well as the US.
Vaxine and Medytox signed a memorandum of understanding on 12 May. The partners will jointly carry out product and process development, clinical trial programme and commercial scale-up for the Australian and Asian markets, including Korea.